The biotechnology company’s revenue topped $6 billion in its latest quarter, beating analyst expectations, driven almost entirely by sales of its mRNA-based vaccine.
The biotechnology company’s revenue topped $6 billion in its latest quarter, beating analyst expectations, driven almost entirely by sales of its mRNA-based vaccine.
Source: Read More
PAID